Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age

Gutman, 1983, Evaluation of a patient with central retinal vein occlusion, Ophthalmology, 90, 481, 10.1016/S0161-6420(83)34528-0 Fong, 1993, Central retinal vein occlusion in young adults, Surv Ophthalmol, 38, 88, 10.1016/0039-6257(93)90063-D Quinlan, 1990, The natural course of central retinal vein occlusion, Am J Ophthalmol, 110, 118, 10.1016/S0002-9394(14)76979-X Williamson, 1996, Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion, Br J Ophthalmol, 80, 203, 10.1136/bjo.80.3.203 Dodson, 1983, B-thromboglobulin and platelet factor 4 levels in retinal vein occlusion, Br J Ophthalmol, 67, 143, 10.1136/bjo.67.3.143 Dodson, 1982, Retinal vein occlusion and prevelance of lipoprotein abnormalities, Br J Ophthalmol, 66, 161, 10.1136/bjo.66.3.161 Glueck, 1999, Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion, Arch Ophthalmol, 117, 43, 10.1001/archopht.117.1.43 Samaha, 1995, Prevelance and patient profile in activated protein C resistance, Am J Clin Pathol, 104, 450, 10.1093/ajcp/104.4.450 Bick, 1992, Hypercoagulability and thrombosis, Hematol Oncol Clin North Am, 6, 1421, 10.1016/S0889-8588(18)30284-3 den Heijer, 1996, Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Eng J Med, 334, 759, 10.1056/NEJM199603213341203 Ames, 1995, Antiphospholipid antibodies, haemostatic variables and thrombosis—a survey of 144 patients, Thrombo Haemost, 73, 768, 10.1055/s-0038-1653866 Engbersen, 1995, Thermolabile 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia, Am J Hum Genet, 56, 142 Wenzler, 1993, Hyperhomocysteinemia in retinal artery and retinal vein occlusion, Am J Ophthalmol, 115, 162, 10.1016/S0002-9394(14)73919-4 Biousse, 1997, Retinal vein occlusion and transient monocular visual loss associated with hyperhomocysteinemia, Am J Ophthalmol, 124, 257, 10.1016/S0002-9394(14)70800-1 Santosh-Kumar, 1997, Unpredictable intra-individual variations in serum homocysteine levels on folic acid supplementation, Eur J Clin Nutr, 51, 188, 10.1038/sj.ejcn.1600385 Thaler, 1981, Antithrombin III deficiency and thromboembolism, Clin Haematol, 10, 369, 10.1016/S0308-2261(21)00229-0 Abu el-Asrar AM, al-Momen AK, al Amro S, et al. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996–97;20:197–204. Bertram, 1995, Protein C, protein S, and antithrombin III in acute ocular occlusive diseases, Ger J Ophthalmol, 4, 332 Zwierzina, 1985, Retinaler Gefässverschluss bei Antithrombin III-Mangel, Klin Monatsbl Augenheilkd, 187, 534, 10.1055/s-2008-1054394 Trope, 1983, Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion, Br J Ophthalmol, 67, 137, 10.1136/bjo.67.3.137 Krüger, 1990, Inhibitoren der Gerinnung bei Gefässverschlüssen der Netzhaut und des Sehnerven, Fortschr Ophthalmol, 87, 178 Guareschi, 1990, Normal activities of protein C protein S and antithrombin III in young patients with retinal vein occlusion [letter], Haematologica, 75, 483 Koster, 1993, Venous thrombosis due to poor anticoagulant response to activated protein C, Lancet, 342, 1503, 10.1016/S0140-6736(05)80081-9 Arruda, 1995, Factor V Leiden (FVQ 506) is common in a Brazilian population, Am J Hematol, 49, 242, 10.1002/ajh.2830490312 Guven, 1999, Risk factors in central retinal vein occlusion and activated protein C resistance, Eur J Ophthalmol, 9, 43, 10.1177/112067219900900107 Greven, 1997, Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance, Am J Ophthalmol, 124, 687, 10.1016/S0002-9394(14)70909-2 Larsson, 1996, Activated protein C resistance in young adults with central retinal vein occlusion, Br J Ophthalmol, 80, 200, 10.1136/bjo.80.3.200 Cierdella, 1998, Factor V Leiden, activated protein C resistance, and retinal vein occlusion, Retina, 18, 308, 10.1097/00006982-199807000-00003 Gottlieb, 1998, Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults, Arch Ophthalmol, 116, 577, 10.1001/archopht.116.5.577 Hodgkins, 1995, Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion, Eye, 9, 760, 10.1038/eye.1995.191 Allart, 1993, Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect, Lancet, 341, 134, 10.1016/0140-6736(93)90003-Y Krüger, 1990, Occlusion ischémique de la veine centrale de la rétine et déficit en protéine C, J Fr Ophthalmol, 13, 369 Scat, 1995, Occlusion veineuse de la rétine et résistance à la protéine C activée. Retinal vein occlusion and resistance to activated protein C, J Fr Ophtalmol, 18, 758 Prince, 1995, Acquired protein S deficiency in a patient with systemic lupus erythematosus causing central retinal vein thrombosis, J Clin Pathol, 48, 387, 10.1136/jcp.48.4.387 Pabinger, 1994, The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency, Thromb Haemost, 71, 441, 10.1055/s-0038-1642457 Giorgi D, Gabrieli CB, Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome [review]. Ocul Immunol Inflamm 1998;6:296–73. Dunn, 1996, Antiphospholipid antibodies and retinal vascular disease, Lupus, 5, 313, 10.1177/096120339600500413 Coniglio, 1996, Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions, Thromb Res, 83, 183, 10.1016/0049-3848(96)00119-3